Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Risk-adapted strategy in HR+/HER2 negative early breast cancer

When can chemotherapy be omitted and how does menopausal status matter?

Date

02 Dec 2022

Session

Risk-adapted strategy in HR+/HER2 negative early breast cancer

Topics

Translational Research; Genetic and Genomic Testing; Therapy

Tumour Site

Breast Cancer

Presenters

Christos Sotiriou

Authors

C. Sotiriou

Author affiliations

Breast Cancer Translational Research Laboratory J.-c. Heuson, Institute Jules Bordet, 1000 - Brussels/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

02 Dec 2022

Defining the risk from clinical assessment to genomic classifiers: Does ethnicity matter?

Presenter: Yoon Sim Yap

Session: Risk-adapted strategy in HR+/HER2 negative early breast cancer

Resources:

Slides

Webcast

02 Dec 2022

Escalating strategies over standard of care as adjuvant treatment therapy in HR+HER2- EBC: Where do we stand?

Presenter: Valentina Guarneri

Session: Risk-adapted strategy in HR+/HER2 negative early breast cancer

Resources:

Slides

Webcast

02 Dec 2022

Q&A and discussion

Presenter: Suzette Delaloge

Session: Risk-adapted strategy in HR+/HER2 negative early breast cancer

Resources:

Slides

Webcast